Asco 2023 – a role for immuno-oncology in ovarian cancer at last?
Every now and then a new drug combination for the treatment of ovarian cancer is announced as the next best thing. Interim results from the Duo-O trial presented at the recent American Society of Clinical Oncology suggest that the addition of immunotherapy to standard chemo for ovarian cancer improves progression free survival (PFS).
Previously the use of immunotherapy, which entails antibody inhibition of checkpoints to the normal immune response, has not been seen to be effective. The Duo trial, which includes the monoclonal antibody Durvalumab together with various cocktails of standard chemo including PARP inhibitors, suggests that PFS is increased for women with ovarian cancer who are not BRCA+ve.
Unfortunately it is too soon to know whether this relates to overall survival, there is a history of previous improvements in PFS, with no overall benefit. Also, the side effects and quality of life on combination therapy are yet to recorded. However, the hoped for targeted immunotherapy for ovarian cancer seems to be more probable with the results from the Duo trial.
No comments:
Post a Comment